Net Product Sales by Geographic Region, Product Line, and Gross Product Sales by Significant Customers (Tables)

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Schedule of Net Product Sales by Geography

The below table presents our net product sales by geography for the years ended December 31, 2015, 2014, and 2013:

Net Product Sales by Geographic Region

	Year Ended December 31,
	2015				2014				2013
United States	$	130,432	95.3	%	$	177,979	95.4	%	$	133,462	93.0	%
International:
Europe (ZEVALIN and FOLOTYN only)	2,234		1.6	%	3,357		1.8	%	3,953		2.8	%
Asia Pacific (ZEVALIN only)	4,185		3.1	%	5,201		2.8	%	6,060		4.2	%
Total International	6,419		4.7	%	8,558		4.6	%	10,013		7.0	%
Net product sales	$	136,851	100	%	$	186,537	100.0	%	$	143,475	100.0	%

Schedule of Net Product Sales by Product Line

Net Sales by Product

The below table presents our net product sales by product for the years ended December 31, 2015, 2014, and 2013:

	Year Ended December 31,
	2015				2014				2013
FUSILEV	$	60,710	44.4	%	$	105,608	56.6	%	$	68,397	47.7	%
FOLOTYN	40,606		29.7	%	47,556		25.5	%	44,370		30.9	%
ZEVALIN	17,457		12.8	%	22,169		11.9	%	29,393		20.5	%
MARQIBO	8,006		5.9	%	6,328		3.4	%	1,315		0.9	%
BELEODAQ	10,072		7.4	%	4,876		2.6	%	—		—	%
Net product sales	$	136,851	100.0	%	$	186,537	100.0	%	$	143,475	100.0	%

Summary of Customers Representing 10% or More of Gross Product Sales

The below table presents the customers that represent 10% or more of our gross product sales in 2015, 2014, and 2013:

	Year Ended December 31,
	2015				2014				2013
Oncology Supply, a division of ASD Specialty Healthcare, Inc., and its affiliates (excluding ICS)	$	78,989	36.7	%	$	115,079	40.4	%	$	79,497	35.4	%
McKesson Corporation and its affiliates	73,577		34.2	%	93,656		32.9	%	44,350		19.8	%
Integrated Commercialization Solutions, Inc. (“ICS”)	*		—	%	*		—	%	35,548		15.8	%
Cardinal Health, Inc. and its affiliates	37,414		17.4	%	*		—	%	*		—	%
All Other Customers	25,156		11.7	%	75,950		26.7	%	64,906		29.0	%
Gross product sales	$	215,136	100.0	%	$	284,685	100.0	%	$	224,301	100.0	%

* Less than